Physician profile
James D Jaco
NPI 1932173069
$9,672.56
in general payments reported to CMS, 2019-2025
23 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $120 · 2021: $421 · 2022: $1,066 · 2023: $2,048 · 2024: $2,322 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,278 · Travel and Lodging: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,278.48 |
| Travel and Lodging | $786.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,874.16 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Cvi Contact Lens |
| Bausch & Lomb Americas INC. | $2,219.42 | 2022-2025 | Infuse, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $594.74 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $498.28 | 2019-2025 | Clareon, Total30 |
| Abbvie INC. | $462.56 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $383.32 | 2019-2022 | |
| Harrow Eye, LLC | $375.95 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $250.90 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $249.55 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $222.19 | 2019 | |
| Sight Sciences, INC. | $218.02 | 2023-2025 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $165.70 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $148.56 | 2019-2021 | |
| Astellas Pharma US INC | $147.66 | 2024-2025 | Izervay |
| Genentech USA, INC. | $146.97 | 2024 | Vabysmo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.86 | 2019-2021 | |
| Rxsight INC | $126.97 | 2022 | |
| Glaukos Corporation | $117.17 | 2021-2025 | Idosetr |
| Horizon Therapeutics Plc | $94.32 | 2021 | |
| Allergan, INC. | $77.28 | 2019-2022 | |
| Lkc Technologies, INC. | $72.32 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $54.92 | 2021 | |
| Dompe US, INC. | $31.74 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.